TAVR vs ABCSizing
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
TAVR
This tool helps healthcare professionals identify patients undergoing transcatheter aortic valve replacement who are at higher risk for 30-day readmission. It utilizes data from a large database to provide a simple risk prediction.
- Risk prediction for TAVR patients
- Identifies 30-day readmission risk
- Uses Nationwide Readmissions Databases
- Aids in transition of care planning
- Simple and easy-to-use interface
Read full descriptionHide full description
Patients undergoing transcatheter aortic valve replacement (TAVR) are at a higher risk of recurrent healthcare resource utilization due to multiple comorbidities, frailty, and advanced age. The 30-day all-cause readmission rate has been reported at 15-20%. We have devised a simple tool to identify patients at higher risk of 30-day readmission using the Nationwide Readmissions Databases (from January 2013 to September 2015). This simple and easy-to-use risk prediction tool may help identify TAVR patients at increased risk of 30-day readmission, and aid in appropriate transition of care upon discharge and post-discharge follow-up. Note: This app (“App)” provides only information, is not medical or treatment advice and may not be treated as such by the user. As such, this App may not be relied upon for the purposes of medical diagnosis or as a recommendation for medical care or treatment. The information on this App is not a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images and information, contained on or available through this App is for general information purposes only
ABCSizing
Read full descriptionHide full description
The app helps clinicians accurately size bicuspid valves for TAVR procedures. Simply input CT scan parameters to receive personalized valve size, inflation volume, and alternative size recommendations. It also evaluates valve fit on important anatomical paramaters like LVOT and annulus, allowing real-time adjustments for precise outcomes. Ideal for optimizing procedural planning and enhancing clinical decision-making. Disclaimer: This app is designed for use by licensed physicians and healthcare professionals. It is intended for informational and reference purposes only and should not be used as a sole source for clinical decision-making. The app's recommendations are based on clinical guidelines and data; however, individual patient circumstances may vary. Users are responsible for exercising their professional judgment when interpreting and applying the app's suggestions. For further information regarding the underlying protocols and citations, please refer to the Support URL provided.
Screenshots
Verdict
The clearest difference is update cadence: ABCSizing at every 3 weeks against TAVR's every 16 months. TAVR's advantage is iOS requirement (10.0 vs 15.1). On price, ads, in-app purchases and device support there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
TAVR ships an update every 16 months, ABCSizing every 3 weeks. The most recent releases landed on September 10, 2026 and September 22, 2026 respectively.
| Parameter | TAVR | ABCSizing |
|---|---|---|
| Price | Free | Free |
| Rating | 5.0 (2 ratings) — better | — |
| Number of ratings | 2 — better | — |
| Update frequency | Every 16 months | Every 3 weeks — better |
| Ads | No | No |
| In-app purchases | No | No |
| Monetization | Free | — |
| Devices | iPhone, iPad, iPod | iPhone, iPad, iPod |
| Requires iOS | 10.0 — better | 15.1 |
| Further details — not scored | ||
| Size | 14 MB | 26 MB |
| Age rating | 12+ | 17+ |
| Developer | Ankur Kalra | Tej Sheth |
In-app purchases
TAVR
No in-app purchases
ABCSizing
No in-app purchases







